PUBLIC COMPANY
save$EWTXEdgewise Therapeutics, Inc.
$EWTX44.04-0.29%Boulder, CO, USupdated 15h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
- phase2Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
- phase2Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- phase1A Study to Evaluate EDG-7500 in People With Renal Impairment
- phase1A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
- phase2A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
- phase2A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
- phase2Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (5)
- Apr 1, 26option exerciseDonovan Joanne M. · CMO28,662 sh
- Apr 1, 26grantFox Jonathan C · 339 sh
- Apr 1, 26option exerciseDonovan Joanne M. · CMO28,662 sh
- Mar 31, 26option exerciseDonovan Joanne M. · CMO21,338 sh
- Mar 31, 26option exerciseDonovan Joanne M. · CMO21,338 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.biopharma_dive · 2mo ago
Data sources
last refreshed 13m ago
Found something off?
comments(0)
5-min edit window · permanent after that